Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 for Non-Hodgkin's Lymphoma

Phase 1

Waitlist Available

Led By Thomas M Habermann

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a combination of a chemotherapy drug and an immune therapy drug for patients with a type of lymphoma that has returned or is resistant to other treatments. The treatment works by both killing cancer cells and boosting the immune system to fight the cancer.

Eligible Conditions

Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Maximum tolerated dose (MTD)

Secondary study objectives

Overall survival

Progression free survival

Tumor response

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (AR160)Experimental Treatment3 Interventions

Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160

2019

Completed Phase 1

~10

Do I qualify?Apply below to find out